DAYTRANA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAYTRANA (DAYTRANA).
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
| Metabolism | Hepatic via carboxylesterase CES1A1 to ritalinic acid; minor CYP2D6 involvement. |
| Excretion | Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites. |
| Half-life | Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal. |
| Protein binding | Approximately 15% bound to plasma proteins. |
| Volume of Distribution | Apparent Vd is approximately 2.65 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Transdermal: Approximately 37% of the nominal dose over the wear period due to residual drug left in patch; conversion from oral methylphenidate is not 1:1, so transdermal dose requires titration. |
| Onset of Action | Transdermal: Clinical effect observed within 1–2 hours of patch application; absorption continues over the 9-hour wear time. |
| Duration of Action | Approximately 9 hours wear per patch; effect persists for up to 12 hours after application; no residual effect after patch removal. |
| Molecular Weight | 269.3 |
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR < 30 mL/min) due to potential for increased exposure. |
| Liver impairment | Not recommended in severe hepatic impairment (Child-Pugh Class C). No adjustment for mild-moderate (Child-Pugh A or B) unless tolerability issues. |
| Pediatric use | Approved for ages 6-12 years: initial dose 10 mg/day as a 9-hour patch; may titrate to 20 mg/day after 1 week. Weight-based: 10 mg for 18-30 kg, 20 mg for >30 kg. |
| Geriatric use | Start at lower end of dosing range (10 mg/day) due to increased sensitivity and higher risk of adverse effects; monitor carefully. |
| 1st trimester | Daytrana (methylphenidate) is not recommended during the first trimester due to potential for fetal cardiac malformations and other developmental effects; limited human data suggest increased risk but not conclusive. |
| 2nd trimester | Use only if potential benefit justifies risk; consider fetal growth restriction and preterm delivery; monitor for maternal hypertension and tachycardia. |
| 3rd trimester | Avoid in third trimester because of risk of neonatal withdrawal (e.g., irritability, feeding difficulties) and possible fetal distress; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for DAYTRANA (DAYTRANA).
| Placental transfer | Methylphenidate crosses the placenta; fetal plasma concentrations are approximately 50-100% of maternal levels based on animal and limited human data. Active transport and efflux mechanisms may modulate transfer. |
| Breastfeeding |
■ FDA Black Box Warning
Methylphenidate has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
| Serious Effects |
Known hypersensitivity to methylphenidate or transdermal system componentsMarked anxiety, tension, or agitationGlaucomaTics or family history of Tourette's syndromeConcurrent use of or within 14 days of MAO inhibitors (serious hypertensive crisis risk)
| Precautions | Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities, Psychiatric adverse reactions (e.g., psychosis, mania), Seizures in patients with history of seizure disorder, Long-term suppression of growth (height and weight) in children, Peripheral vasculopathy including Raynaud's phenomenon, Potential for allergic reactions to transdermal system components |
| Food/Dietary | Avoid excessive consumption of caffeine (coffee, tea, cola) and other stimulants as they may increase side effects like nervousness and insomnia. No specific food restrictions; however, high-fat meals before application do not affect absorption due to transdermal delivery. |
Loading safety data…
| Methylphenidate is excreted into breast milk in low concentrations (relative infant dose approximately 0.2-0.7% of maternal weight-adjusted dose). However, cases of infant irritability, poor feeding, and insomnia have been reported. Use caution and monitor infant for adverse effects; avoid if infant has baseline cardiac or seizure disorders. American Academy of Pediatrics considers it 'maternal medication usually compatible with breastfeeding' but recommend monitoring. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Teratogenic risk is undefined due to insufficient human data. Animal studies suggest potential for embryotoxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: Use only if maternal benefit justifies fetal risk; may cause fetal tachycardia, growth restriction, or behavioral effects. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight. Monitor fetal growth and heart rate; consider serial ultrasound for growth parameters. Assess for preterm labor or placental abruption symptoms. |
| Fertility Effects | No specific human data on fertility effects. Animal studies show no significant reproductive impairment at therapeutic doses. Theoretical risk of hypothalamic-pituitary-gonadal axis modulation. |
| Clinical Pearls | Daytrana (methylphenidate transdermal system) is a Schedule II controlled substance. Apply to clean, dry, non-irritated skin on the hip, alternating sides daily. Remove after 9 hours to avoid circadian rhythm disruption. Avoid exposing the application site to direct heat (heating pads, saunas) which increases absorption rate. Monitor for hypertension, tachycardia, and growth suppression in children. Discontinue if agitation or psychosis emerges. |
| Patient Advice | Apply the patch to the hip area only, not on the waistline where clothing may rub it off. · Remove the patch after 9 hours; do not wear it for longer. · Do not cut or modify the patch. · Avoid heat sources (heating pads, electric blankets) near the patch site. · Wash hands after applying or removing the patch. · Store patches in a safe place away from children; dispose of used patches by folding adhesive sides together. · Report any skin irritation, chest pain, or mood changes to your doctor. |